Ikena Oncology (NASDAQ:IMA - Get Free Report) had its target price cut by investment analysts at Wedbush from $25.00 to $23.00 in a research note issued on Friday, MarketBeat Ratings reports. The brokerage presently has a "neutral" rating on the stock. Wedbush's price target points to a potential upside of 51.02% from the company's current price.
Ikena Oncology Price Performance
NASDAQ IMA traded down $1.14 during midday trading on Friday, hitting $15.23. 19,711 shares of the company traded hands, compared to its average volume of 13,221. The company has a market cap of $735.00 million, a PE ratio of -23.80 and a beta of 0.50. The company's 50-day simple moving average is $15.51 and its 200-day simple moving average is $15.67. Ikena Oncology has a 52 week low of $11.65 and a 52 week high of $23.28.
Ikena Oncology (NASDAQ:IMA - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08. On average, research analysts predict that Ikena Oncology will post -0.91 earnings per share for the current year.
Hedge Funds Weigh In On Ikena Oncology
Several hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock valued at $255,000 after acquiring an additional 154,892 shares during the last quarter. Geode Capital Management LLC lifted its position in Ikena Oncology by 21.0% during the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after purchasing an additional 56,936 shares during the period. Gilead Sciences Inc. acquired a new position in Ikena Oncology during the fourth quarter valued at $3,294,000. Northern Trust Corp boosted its holdings in Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock valued at $94,000 after purchasing an additional 9,456 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Ikena Oncology during the 4th quarter worth about $72,000. Institutional investors and hedge funds own 75.00% of the company's stock.
About Ikena Oncology
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Stories
Before you consider ImageneBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImageneBio wasn't on the list.
While ImageneBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access